Fatty Liver (MASLD): Early Red Flags, Tests and Stages Explained Simply

A pooled analysis of Indian studies found fatty liver in 38.6% of adults — and 35% of children, mostly those with obesity (Shalimar et al., 2022). It is now called MASLD (metabolic dysfunction-associated steatotic liver disease). The name is not just a label: the diagnosis needs fat in the liver plus at least one cardiometabolic criterion — raised waist, raised blood sugar or diabetes, raised blood pressure, raised triglycerides or low HDL — after other causes such as significant alcohol intake, hepatitis or certain medicines have been considered. (Heavy alcohol intake alongside these features is classified separately, as MetALD.)

How to read a “normal” report

• Lab “normal” ranges are broad and population-based.
• One normal report is not an all-clear; one abnormal value is not a disease.
• Decide using pattern + trend + risk — with your doctor.

Metabolic red flags to spot early

1. Body shape

• Waist-to-height ratio 0.5 or more = central fat (NICE 2022). Easy rule: your waist should be less than half your height.
• Quick guide: height 150 cm → waist under 75 cm · 160 → under 80 · 170 → under 85 · 180 → under 90.
• Indian cut-offs: waist ≥90 cm in men, ≥80 cm in women (Misra et al., 2009).
• Measure midway between the lowest rib and the top of the hip bone, standing relaxed, after breathing out normally.

2. Blood pressure

Sit quietly for 5 minutes, back supported, feet flat, arm at heart level, no caffeine or exercise for 30 minutes before. 130/85 mmHg or higher (or being on BP medicine) is a metabolic flag.

3. Lipids

Triglycerides 150 mg/dL or more, or HDL below 40 (men) / 50 (women), are flags. Some doctors also look at the TG-to-HDL ratio as a rough sign of insulin resistance, but there is no single agreed cut-off.

4. Blood sugar (ADA 2026)

Fasting glucose 100–125 mg/dL or HbA1c 5.7–6.4% = prediabetes; 126+ or 6.5%+ = diabetes range (needs confirmation).

5. Insulin resistance (HOMA-IR)

HOMA-IR = fasting glucose (mg/dL) × fasting insulin (µU/mL) ÷ 405. (If your lab reports glucose in mmol/L, the divisor is 22.5 — check the units before comparing reports.) Higher means more insulin resistance, but cut-offs vary between labs and populations, so use it as a trend with the same lab — not as a stand-alone diagnosis. It is not a routine test for everyone.

6. Liver enzyme patterns

• In early fatty liver, ALT is often higher than AST — even when both are within the “normal” range. But this is a pattern, not a test: liver enzymes can be completely normal in MASLD, including in some people who already have fibrosis, so a normal ALT does not rule it out.
• A concern for more advanced scarring is AST higher than ALT with low or falling platelets.
• AST can also rise with muscle injury, heavy exercise, thyroid problems, alcohol, medicines or hepatitis — context matters.
• GGT, uric acid and hs-CRP (when well) can add clues, but are not diagnostic on their own.

Tests your doctor may start with

Group	Tests
Metabolic	Fasting glucose, HbA1c, lipid profile (± non-HDL/ApoB)
Liver	ALT, AST, GGT, ALP, bilirubin, albumin, platelets (INR if advised)
Context	TSH, ferritin, uric acid, hepatitis B and C tests if advised

Staging without a biopsy

1. Ultrasound — shows fat in the liver (but not scarring).
2. FIB-4 score — calculated from age, AST, ALT and platelets. Below 1.3 = low risk of advanced scarring; 1.3–2.67 = indeterminate; above 2.67 = high (for age 65+, below 2.0 counts as low). Recommended as the first step by AASLD (2023). FIB-4 is less reliable below about age 35 and during acute illness, and anything that changes platelets or liver enzymes (infection, an alcohol binge, another liver disease) can distort the score.
3. FibroScan (transient elastography) — CAP measures fat; stiffness (kPa) estimates scarring. Used if FIB-4 is not low or risk is high. Cut-offs depend on the machine and cause, so a specialist interprets them.
4. MRI-based tests or biopsy — only when results are unclear or to guide treatment.

Stages of fatty liver in plain words

Stage	What it means
1. Steatosis (MASLD)	Fat in the liver; little or no inflammation. Usually silent.
2. MASH	Fat plus inflammation and liver-cell injury.
3. Fibrosis (F1–F3)	Scar tissue builds up, from mild to bridging.
4. Cirrhosis (F4)	Advanced scarring. “Compensated” = the liver still copes; “decompensated” = complications like fluid in the belly, bleeding, jaundice or confusion.

What usually happens next?

• Progression is slow and varies a lot: on average about 1 fibrosis stage every 14 years with simple fatty liver, and every 7 years with MASH (Singh et al., 2015).
• Early fatty liver is often reversible. In a large study, people who lost 10% or more of their weight had the greatest improvement — including in scarring (Vilar-Gomez et al., 2015). Even 5% helps reduce liver fat; 7–10% improves inflammation.
• The leading cause of death in people with MASLD is heart disease, not liver failure — so BP, sugar and cholesterol control matter as much as the liver.

Quick action checklist

• No sugary drinks, and no alcohol while trying to reverse fatty liver
• Mostly home-cooked meals: vegetables, dal/protein, whole grains, measured oil
• Aim to lose 7–10% of body weight gradually (about 1–2% a month) if overweight
• 150+ minutes a week of activity plus 2–3 strength sessions
• Finish dinner a few hours before bed
• Follow up with your doctor: FIB-4 first, FibroScan if needed

I’m not a medical doctor — I’m a Nursing Officer with an MPH, sharing evidence-based information to help you understand your health.

Related reading

• Lower triglycerides and liver fat in 30 days
• Glucose spikes and how to steady your blood sugar
• Intermittent fasting: who it suits and who it does not

Sources

1. Shalimar et al. Prevalence of NAFLD in India: systematic review and meta-analysis, J Clin Exp Hepatol (2022) — about 1 in 3 Indian adults (38.6% pooled) have fatty liver
2. Rinella ME et al. AASLD Practice Guidance on clinical assessment and management of NAFLD/MASLD, Hepatology (2023) — FIB-4 first, then elastography; weight-loss targets
3. Duseja A et al. INASL Guidance Paper on NAFLD, J Clin Exp Hepatol (2023) — Indian guidance on diagnosis and treatment
4. Singh S et al. Fibrosis progression in NAFL vs NASH: meta-analysis of paired-biopsy studies, Clin Gastroenterol Hepatol (2015) — about 1 stage per 14 years (fat only) vs per 7 years (MASH)
5. Vilar-Gomez E et al. Weight loss through lifestyle modification reduces features of NASH, Gastroenterology (2015) — ≥10% weight loss led to the biggest improvements, including fibrosis
6. Misra A et al. Consensus statement on obesity for Asian Indians, JAPI (2009) — waist 90/80 cm
7. NICE. Keep your waist to less than half your height (2022) — waist-to-height ratio
8. American Diabetes Association. Standards of Care in Diabetes 2026 — Diagnosis — glucose and HbA1c cut-offs